Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.

Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health (CVS – Research Report) on January 10 and set a price target of ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price ...